Skip Navigation

Adalvo announces successful launch of Vinorelbine

14 December 2022

Adalvo is pleased to announce that we have successfully launched Vinorelbine soft gel capsules in Israel.

The product has been developed based on the reference brand NAVELBINE, and is indicated in the treatment of non-small cell lung cancer and advanced breast cancer. The brand sold around $112mio globally in 2021, according to IQVIA.

The product is being developed by our sister company, which forms part of the Aztiq group, having a state-of-the-art R&D and manufacturing facility, with several GMP inspections already successfully completed.

Alvogen/Adalvo was the first company to launch this complex technology product in the UK, back in 2019, proving our ability to bring high-value products to the market. With the launch in Israel, we are extending market reach, bringing medications to more people in need.